Capsulomics
2 known investors
Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
AI & Machine LearningDigital HealthMedical Devices
Investors · 2
In the news
- Good News: Haystack Oncology Acquired, Scene Health Raises $17.7M - Johns Hopkins Technology Venturesventures.jhu.edu · 2023
- PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY'S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST - BioSpacebiospace.com · 2023
- Previse Closes $3M in Seed Fundingfinsmes.com · 2023
- Power Moves: Capsulomics nabs ex-Delfi Diagnostics CFOtechnical.ly · 2022
- Tech startup Capsulomics hires former PGDx CFO Bill Stevens as it looks to raise seed round - Baltimore Business Journalbizjournals.com · 2022
- Capsulomics establishes $3.7 Million NIH-funded research collaboration with Johns Hopkins Universityprnewswire.com · 2020